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Abstract
Breast cancer incidence rates have declined among older but not younger women; the latter are
more likely to be diagnosed with breast cancers carrying a poor prognosis. Epidemiological
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evidence supports an increase in breast cancer incidence following pregnancy with risk elevated as
much as 10 years postpartum. We investigated the association between years since last full-term
pregnancy at the time of diagnosis (≤10 or >10 years) and breast tumor subtype in a case series of
premenopausal Hispanic women (n = 627). Participants were recruited in the United States,
Mexico, and Spain. Cases with known estrogen receptor (ER), progesterone receptor (PR), and
HER2 status, with one or more full-term pregnancies ≥1 year prior to diagnosis were eligible for
this analysis. Cases were classified into three tumor subtypes according to hormone receptor (HR+
= ER+ and/or PR+; HR− = ER− and PR−) expression and HER2 status: HR+/HER2−, HER2+
(regardless of HR), and triple negative breast cancer (TNBC). Case-only odds ratios (ORs) and
95% confidence intervals (CIs) were calculated for HER2+ tumors in reference to HR+/HER2−
tumors. Participants were pooled in a mixed-effects logistic regression model with years since
pregnancy as a fixed effect and study site as a random effect. When compared to HR+/HER2−
cases, women with HER2+ tumors were more likely be diagnosed in the postpartum period of ≤10
years (OR=1.68; 95% CI, 1.12–2.52). The effect was present across all source populations and
independent of the HR status of the HER2+ tumor. Adjusting for age at diagnosis (≤45 or >45
years) did not materially alter our results (OR=1.78; 95% CI, 1.08–2.93). These findings support
the novel hypothesis that factors associated with the postpartum breast, possibly hormonal, are
involved in the development of HER2+ tumors.
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Introduction
Although incidence rates of invasive breast cancer in the U.S. have decreased slightly over
time, this trend has not been observed among younger women, in whom there is evidence
for substantial racial/ethnic disparities [1,2]. While the overall proportion of breast cancer
occurring in women age <40 years is only 5.6%, it is higher for U.S. Hispanics (10.3%) [1],
for whom age at diagnosis has been shown to be as much as ten years earlier than non-
Hispanic Whites (NHWs) [3–5]. Furthermore, despite lower incidence rates than in the U.S.,
the average age at diagnosis in Mexico is 50.1 years [6], approximately six years younger
than for U.S. Hispanics [7,3]. In Mexico, it is estimated that 45% of cases are diagnosed in
women age <50 years [6], while this proportion is 36% for U.S. Hispanics and 21% for
NHWs [6,1].
Clinically, breast cancer represents a heterogeneous disease that is grouped based on its
hormone receptor (HR) status (estrogen receptor [ER] or progesterone receptor [PR]
positivity) and amplification of the ERBB2 gene (hereafter referred to as HER2+) [8].
Genomic profiling has identified at least two major lineages (i.e., luminal and basaloid) that
split predominantly on their HR status [9,10]. These breast tumor subtypes differ by age at
diagnosis, race/ethnicity, reproductive patterns, lifestyle factors, stage at diagnosis, and
survival [11–14]. Recent epidemiologic and genetic studies support the concept of
underlying etiologic heterogeneity of breast tumor subtypes [15]. For example, breast cancer
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risk differs by age at onset and menopausal status [16,17], as well as timing and number of
births [18,19], depending on its HR status.
Findings from large, prospective studies provide strong evidence for a “dual” effect of
pregnancy, where a transient postpartum increase in breast cancer risk is followed by long-
term reduction in risk, relative to nulliparous women [20,18]. Depending on factors such as
number of births and age at last birth, the estimated peak in breast cancer risk in the
postpartum period ranges from 3–7 years, persisting for 10 or more years [21,20,22].
Further, it has been suggested that two forms of cancer are associated with pregnancy [23–
26]. One, referred to as pregnancy associated breast cancer (PABC), is thought to involve
those tumors that are diagnosed during or within the first year after a pregnancy; the other
consists of tumors diagnosed in the postpartum period (more than one year after birth). The
distinction is based on observed differences in mortality risk according to the time of
diagnosis relative to pregnancy. Cases diagnosed in the postpartum period experience a
higher risk of mortality than those diagnosed during pregnancy, after taking stage and other
prognostic markers into account [25]. However, these observations have considered breast
cancer as a single entity, and little is known about how, or if, this increase in risk differs by
tumor subtype.
With the recognition of what appear to be distinct etiological paths to breast tumorigenesis,
the complex role of pregnancy as a risk factor for breast cancer in younger women has
gained a renewed interest. In vitro and in vivo studies provide evidence of critical cross-talk
between progesterone/PR and estrogen/ER, possibly ER, and heregulin/HER2 signaling
transduction pathways and a contribution of hormones or hormone conditioning of the breast
in the activation of HER2 [27–29]. There are no known risk factors for the development of
HER2+ tumors, and few epidemiological studies have assessed HER2+ tumors as a separate
subgroup. Kwan et al. [30], showed that the odds of HER2-overexpressing tumors, defined
as HR−/HER2+, were significantly greater in younger women, Asian and Hispanic women,
and cases with 3 or more children who never breastfed when compared to cases with luminal
A (HR+/HER2−) tumors. Analyses for HER2+ tumors independent of HR status were not
considered separately.
Data from our previous genomic study of early-stage breast tumors show that HER2+
tumors are genetically more similar to each other than to HR+/HER2− or triple negative
breast cancer (TNBC) [31]. We therefore speculate that, at least at the DNA level, HER2+
tumors may represent a subset of breast cancers that arise under distinct etiological
influences, regardless of HR status. Here, we hypothesize that hormone exposure during
pregnancy or lactation/involution confers a selective pressure for the outgrowth of cells
harboring disturbances in HER2 signaling, independent of their hormone receptor status.
Given the younger age at diagnosis and higher fertility rates in Hispanics compared with
NHWs [32], we explored associations between pregnancy-related factors and HER2+ breast
cancer in a case series of Hispanic women. Specifically, we investigated the association
between the number of years since the last full-term pregnancy at the time of diagnosis and
HER2+ tumors.
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Materials and Methods
Study population
We pooled data from two Hispanic case series: the Ella Binational Breast Cancer study
(Ella) and the Breast Oncology Galician Network (BREOGAN) study. Ella comprises 1,515
patients diagnosed with invasive breast cancer in the previous 24 months. Participants were
recruited between 2007–2010; the present analysis includes data available by July 11, 2011.
This multi-center study includes two sites in the U.S. [the Arizona Cancer Center (AZCC) in
Tucson, Arizona and the M.D. Anderson Cancer Center (MDACC) in Houston, Texas] and
three sites in Mexico [the Universidad de Sonora (UNISON) in Hermosillo, Sonora; the
Instituto Tecnológico de Sonora (ITSON) in Ciudad Obregón, Sonora; and the Universidad
de Guadalajara (UG) in Guadalajara, Jalisco]. All recruitment sites used a predominately
clinic-based recruitment strategy. A detailed description of the organizational structure and
methods of the study has been previously described [33]. Women were eligible to participate
if they were diagnosed with incident invasive breast cancer, were age 18 years or older, and
self-identified as Mexican or Mexican-American. Risk factor characteristics, including a
detailed pregnancy history and menopausal status at the time of diagnosis, were collected
via an interviewer-administered questionnaire [33]. Age at diagnosis was abstracted from
medical records. All participants provided written informed consent. The Institutional
Review Board (IRB) from each participating institution approved the study protocol.
The BREOGAN study is a population-based study conducted in the cities of Vigo and
Santiago de Compostela, Spain. A total of 979 invasive and in situ breast cancer cases
diagnosed between 1997–2012 were recruited at the Clinical University Hospital of Vigo
and the Clinical University Hospital of Santiago de Compostela. Risk factor information was
abstracted from patient medical records using the Ella risk factor questionnaire format for
consistency between U.S. and Mexico datasets. Age at diagnosis, pregnancy history, and
other reproductive factors are routinely obtained as part of the comprehensive patient
medical record system in Spain. All participants provided written informed consent. The
study was conducted in accordance to the Helsinki Principles of 1975, as revised in 1983.
The Galician Ethics and Research Committee (CEIC, Comité Ético de Investigación Clínica
de Galicia), responsible for the oversight of both university hospitals, approved the study
protocol.
Tumor marker classification
In both studies, trained physicians abstracted tumor marker data from medical records. In the
Ella study, ER and PR were classified as positive or negative according to the most recent
guidelines [34]. In the abstraction, priority was given to a numeric value for the percent of
cells staining. Any positive staining (≥1% of cells) resulted in ER/PR classified as positive.
In 13.1% of cases, no specific number for percent of cells staining was available. We
therefore used the interpretation value (“negative”, “positive”, or “low positive”) with any
positive staining interpreted as positive. For the BREOGAN study, the cut-point for ER/PR
was set at <10% as negative and ≥ 10% as positive. Had Ella used the higher cut-point, an
additional 2% of cases would have been classified as ER/PR negative. For HER2 status,
priority was given to determination by fluorescent in situ hybridization over
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immunohistochemistry (IHC). IHC values of 0 and 1+ were considered negative, 2+
equivocal, and 3+ positive [35].
Statistical methods
Analyses were restricted to premenopausal women with a known diagnosis of invasive
breast cancer (n=898). We limited our focus to early-onset, premenopausal cases to
minimize heterogeneity introduced by menopause on breast cancer risk and to assess the
effect of pregnancy during reproductive years. Time (years) since last full-term pregnancy
was calculated using age at diagnosis and age at last full-term pregnancy, where a full-term
pregnancy was defined as one lasting >5 months, regardless of outcome. Cases with
equivocal HER2 status not confirmed by FISH (n=31), missing tumor marker information
(n=122), or zero full-term pregnancies (n=106) were excluded. We further excluded
participants with missing information on age at first and/or last pregnancy (n=2) and those
with a full-term pregnancy <1 year prior to diagnosis (n=10). After applying inclusion and
exclusion criteria, 627 cases were available for analysis (414 from Ella and 213 from
BREOGAN).
We dichotomized time since last full-term pregnancy as ≤10 or >10 years, based on
evidence supporting a window of increased risk and poor survival in the postpartum period
[36,37]. Surrogates of tumor subtypes were approximated according to joint ER, PR, and
HER2 status. Breast tumors were classified as HR+ if they were ER+ and/or PR+ and HR-
negative if ER− and PR−. Tumors were grouped into the following subtypes: HR+/HER2−,
HER2+ (independent of HR), and TNBC (HR− and HER2−). We classified HER2+ tumors
independent of their HR status under the a priori hypothesis that ERBB2 amplification arises
as a consequence of an unknown, but distinct, etiological event. Our analysis is based on the
working assumption that the aforementioned tumor subtypes represent three different forms
of breast cancer.
All statistical analyses were performed using Stata 12.1 (StataCorp, College Station, TX).
Descriptive statistics (mean ± SD and proportions) for reproductive and clinical
characteristics were calculated separately by country of recruitment (USA, Mexico, or
Spain). Potential associations between each risk factor and HER2+ status were tested using
t-tests (continuous variables) or Fisher’s exact tests (categorical variables) in each country
separately. The crude association between time since last full-term pregnancy (≤ 10 vs. > 10
y) and HER2+ status was tested using logistic regression, with either HR+/HER2− tumors or
TNBC as the reference group.
Participants from all 3 countries were pooled in a mixed-effects logistic regression model,
with time since last full-term pregnancy and age at diagnosis (≤ 45 or > 45 y) included as
fixed effects and study site as a random effect. This approach is advantageous as it allows us
to combine smaller study groups into a larger dataset and model distributions of exposure
variables across sites. Importantly, the pooled approach is defensible in this context because
BREOGAN used the same risk factor instrument to abstract pregnancy history as Ella. In
addition, to examine the robustness of our findings and to test for heterogeneity of effects
across study sites, we also conducted a 2-stage random effects meta-analysis where site-
specific effects were calculated in the first stage, and site-specific estimates were aggregated
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using a random effects model in the second stage [38]. In order to assess heterogeneity of
effect by study site, we calculated the I2 and χ2 (Q) statistics using the metan command in
Stata [39].
Reported associations between HER2+ tumors and reproductive factors include age at
menarche [40,41], parity [30,42], age at first birth [12,30,43], lifetime duration of
breastfeeding [12], and ever using oral contraceptives [30]. We considered all of these
factors plus additional characteristics listed in Table 1 as potential confounders in our
analysis. We did not find any variables associated with both HER2+ tumors and time since
last full-term pregnancy. Previous studies have reported an association between HER2+
tumors and age at diagnosis [12,30]. Although age at diagnosis was not associated with
HER2+ in our data, we report age-adjusted pooled estimates as a sensitivity analysis.
Additionally, in order to assess whether categorization of HER2+ tumors independent of HR
status affected our estimates, we compared HER2+/HR+ and HER2+/HR− cases separately
to the referent category. We considered a two-sided p-value of < 0.05 to be statistically
significant.
Results
Descriptive characteristics of the study populations by country
Table 1 presents reproductive and clinical characteristics by country of recruitment. The
mean interval of time between last full-term pregnancy and breast cancer diagnosis for the
U.S., Mexico, and Spain was 13.1, 13.8, and 15.5 years, respectively. Approximately one-
third of cases (range 28.2% to 39.4%) were diagnosed ≤10 years after their last full-term
pregnancy. U.S. cases were younger at diagnosis and had the youngest age at first full-term
pregnancy compared with cases recruited in Mexico or Spain. On average, Mexican
participants had a greater number of full-term pregnancies (3.0), followed by U.S. and
Spanish women. The majority of women in all countries reported breastfeeding their
children, with prevalence ranging from 89% in Mexico to 67.4% in Spain. Not considering
number of births, Spanish women had a shorter mean interval between the first and last
pregnancy than those in the U.S. or Mexico. The majority of cases in all three countries were
classified as HR+/HER2−: 70.0% in Spain, 61.0% in the U.S., and 55.2% in Mexico;
TNBCs were the least common subtype: 17.1%, 22.1%, and 11.3% in U.S., Mexican, and
Spanish women, respectively. Relatively little variation was observed for HER2+ tumors,
which made up 22.8%, 21.9%, and 18.8% of cases in Mexico, the U.S. and Spain,
respectively.
Reproductive and clinical characteristics and HER2+ tumors
The characteristics of HR+/ HER2− and HER2+ cases by country are presented in Table 2.
No statistically significant differences were observed in reproductive characteristics between
HR+/HER2− and HER2+ cases, with the exception of time since last full-term pregnancy
(≤10 vs. >10 y) in Spain. When we evaluated the interval between last full-term pregnancy
and breast cancer diagnosis, we observed no difference in the prevalence of HER2+ tumors
for women whose diagnosis occurred within 5 years following a pregnancy (24.1%) and
those occurring in 5–10 years (26.9%). This was our justification for selecting 10 years after
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pregnancy as the interval to define postpartum cases. Furthermore, we excluded cases within
one year of pregnancy or pregnant at diagnosis to differentiate post-partum breast cancers
from PABC. Participants with HER2+ tumors were more likely to be diagnosed ≤10 years
since their last full-term pregnancy than HR+/HER2− tumors. The proportion of HER2+
tumors diagnosed ≤10 years was 42.5% in Spain, 36.4% in Mexico, and 45.8% in the U.S.,
while the respective proportions for HR+/HER2− tumors were 22.8%, 26.3%, and 39.6%.
Although not reaching statistical significance at the 5% level, HER2+ cases in Mexico were
more likely to be younger at first and last pregnancies than HR+/ HER2− cases.
Time since last full-term pregnancy and HER2+ tumors
Table 3 presents country-specific and pooled odds ratios (ORs) for the association between
time since last full-term pregnancy (≤ 10 vs. > 10 years) and tumor subtype (HER2+ vs. HR
+/HER2−). Country-specific ORs varied in magnitude but not in direction of effect. ORs
(95% confidence intervals) for each study site ranged from 1.04 (0.40–2.67) for AZCC to
4.50 (0.49–41.25) for UNISON (Figure 1). The pooled point estimate calculated using a
random effects model of HER2+ versus HR+/HER2− tumors was OR=1.68 (1.12–2.52).
The 2-stage meta-analytic point estimate of the OR was also 1.68 with heterogeneity
statistics I2 = 0.0% and χ2 (Q) =3.13 (p=0.68). Adjusting for age at diagnosis (≤45 or >45 y)
only marginally affected the estimate (OR=1.78; 95% CI, 1.08–2.93). Results remained
significant in analyses treating age at diagnosis as a continuous variable (OR=2.15; 95% CI,
1.26–3.67).
Further, when we considered the HR status of HER2+ tumors in the association between
time since last full-term pregnancy and HER2 status, we found no evidence of a difference
by HR status. The OR (95% CI) for HR+/HER2+ was 1.71 (1.05–2.82) and that for HR−/
HER2+ was 1.54 (0.84–2.80). Lastly, when we compared the odds of having HER2+ tumors
compared to TNBCs for time since last full-term pregnancy, a positive, albeit non-
significant association was observed. Country-specific positive associations between time
since last full-term pregnancy and HER2+ compared to TNBCs were observed for the U.S.
(OR=1.93; 95% CI, 0.86–4.34) and Spain (OR=1.31; 95% CI, 0.47–3.68) but not Mexico
(OR=0.57; 95% CI 0.21–1.54). The pooled OR (95% CI) was 1.21 (0.71–2.05), and the age-
adjusted pooled OR (95% CI) was 1.84 (0.97–3.50).
Discussion
To our knowledge, this is the first case-only report examining the distribution of tumor
subtypes by time since last full-term pregnancy in a large sample of premenopausal women
with high parity. Our results indicate that HER2+ tumors have higher odds of being
diagnosed in the 10-year period following a full-term pregnancy than HER2− tumors, an
increase in odds that appears to be independent of HR status. The results were consistent
across all three countries, increasing the validity of these findings.
Several groups have investigated the association between reproductive factors and tumor
subtypes [12,44,41,43,42,45,46,40,30,14], but results for HER2+ tumors have been
inconclusive. Few studies have reported on the association between a recent pregnancy and
HER2+ tumors [12,47,48]. Two case-control studies [47,48] reported no association
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between time since pregnancy and HER2+ tumors. In a third, a case-only analysis [12] using
HR+/HER2− tumors as the reference, HR−/HER2+ tumors were more prevalent in cases
diagnosed ≤5 years (OR= 5.05; 95% CI, 1.43–17.86) and >5 years (OR=2.14; 95% CI, 0.86,
5.34) since last pregnancy than in nulliparous women. However, no association was
observed with HR+/HER2+ tumors. Only one of the previous studies [47] excluded
pregnant cases and no exclusions were made based on time since pregnancy in any other
study. All three studies categorized time since last pregnancy into shorter intervals of 2
[48,47] or 5 years [12], and all three were consistent in finding increased odds of HR- or
TNBC tumors during this time period. Also consistent across studies, the association with
recent pregnancy and TNBC or HR- tumors disappeared after the first couple of years
postpartum.
There are numerous reasons for inconsistency between these and our findings, including
choice of reference group, sample size and case-control or case-only study design. A
limitation of our study is the lack of a nulliparous referent group. The small proportion of
nulliparous cases in our study precluded their inclusion in our analyses. Other considerations
include the differences in HER2 classification. In most epidemiological studies conducted to
date, HER2+ tumors have been separated by their HR status, with HR+/HER2+ classified as
luminal B [11,49,30,12,14,40,45,42]. This hierarchical-based classification of breast tumors
is not entirely consistent with gene expression studies [10], and the appropriateness of such
grouping for etiological studies has been debated [50]. Our results indicate that the positive
association between time since last full-term pregnancy and HER2+ tumors (relative to HR
+/HER2− tumors) is independent of HR status. Confirmation of our findings would suggest
that HER2+ tumors may derive from a distinct set of etiological factors than either HR+/
HER2− or TNBC that would be more consistent with the genomic character of the disease at
the genome level [31].
While our study provides evidence for higher odds of HER2+ tumors in the postpartum
period relative to HR+/HER2− tumors, future larger studies would be valuable to assess
finer postpartum intervals, as well as the effect of other reproductive characteristics (e.g.,
age at first birth, number of births, interval between births, and breast feeding) as potential
modifiers of the associated risk. Replication of our findings of differential risk by time since
last pregnancy in the context of parity may provide a partial explanation for the reported
disparities observed among certain populations that have a higher rate of parity (i.e., African
American and Hispanic women) when compared to those that exhibit lower parity rates
(NHWs).
While novel, our findings need confirmation in studies with different control populations
(i.e. non-diseased, nulliparous), particularly because ours can address heterogeneity in the
association by tumor subtype only [15]. It is possible our results are due to selection bias.
The exclusion of cases with incomplete tumor markers and difference in tumor marker
classification might be a source of confounding that is difficult to address. By country, the
proportion of otherwise-eligible participants missing tumor markers was 2% (n=7) in the
U.S., 23% (n=50) in Mexico, and 14% (n=34) in Spain. Although the direction of effect is
consistent across all studies, it is important to note that there is variability in the site-specific
ORs (Figure 1: AZCC OR=1.04 versus UNISON OR=4.5). An advantage of our meta-
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analytic approach is that it provides an estimate derived as a weighted average of results
across study sites. The pooled OR of 1.68 reflects the greater weight given to larger sites
such as Arizona relative to smaller sites such as UNISON. Furthermore, the consistency of
our findings across the three countries is striking, especially as it is highly likely that a
number of sources of residual confounding are present in our data.
These findings extend previous observations [11,30] that the relative proportion of specific
breast tumor subtypes in a population may arise from differences in reproductive factors to
include consideration of time since last pregnancy. In addition, our results support the
possibility that hormonal influences related to pregnancy may contribute to the development
of HER2+ tumors. These results are consistent with recent mechanistic studies
demonstrating cross-talk between HER2 and certain pregnancy-associated hormones. While
a hypothesis, we believe these findings are significant and warrant additional study since
HER2+ tumors have no recognized risk factor(s).
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Fig. 1. Forest plot of the association between time since last full-term pregnancy (≤10 vs. 10
years) and HER2+ tumors versus HR+/HER2− tumors
Study sites: AZCC (Arizona Cancer Center, USA), MDA (M.D. Anderson Cancer Center,
USA), UNISON (Universidad de Sonora, Mexico), ITSON (Instituto Technológico de
Sonora, Mexico), UDG (Universidad de Guadalajara, Mexico), and BREOGAN (Breast
Oncology Galician Network, Spain).
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Time since last full-term pregnancy (y), n (%)
  > 10 163 (60.6) 96 (66.2) 153 (71.8)
  ≤ 10 106 (39.4) 49 (33.8) 60 (28.2)
  Mean ± SD 13.1 ± 7.8 13.8 ± 7.3 15.5 ± 8.1
Total full-term pregnancies, n (%)
  1–2 119 (44.2) 56 (38.6) 177 (83.1)
  3+ 150 (55.8) 89 (61.4) 36 (16.9)
  Mean ± SD 2.8 ± 1.3 3.0 ± 1.4 1.9 ± 0.7
Age at first full-term pregnancy (y), n (%)
  ≤ 23 169 (62.8) 83 (57.2) 97 (45.5)
  > 23 100 (37.2) 62 (42.8) 116 (54.5)
  Mean ± SD 22.5 ± 5.4 23.0 ± 5.3 25.1 ± 5.4
Age at last full-term pregnancy (y), n (%)
  ≤ 30 149 (55.4) 68 (46.9) 122 (57.3)
  > 30 120 (44.6) 77 (53.1) 91 (42.7)
  Mean ± SD 29.7 ± 5.7 30.5 ± 5.2 29.6 ± 5.9
Interval between first and last pregnancy (y)
  Mean ± SD (if parity > 1) 8.5 ± 5.5 8.5 ± 5.3 6.4 ± 4.7
Lifetime breastfeedinga (mo), n (%)
  Never 79 (29.4) 16 (11.0) 69 (32.6)
  ≤ 12 115 (42.8) 60 (41.4) 113 (53.3)
  > 12 75 (27.9) 69 (47.6) 30 (14.2)
  Mean ± SD 11.5 ± 16.2 21.5 ± 29.2 6.4 ± 9.8
Age at menarche (y)
  Mean ± SD 12.6 ± 1.7 12.8 ± 1.5 12.8 ± 1.6
Hormone contraceptive use, n (%)
  Never 84 (31.2) 45 (31.0) 82 (38.5)
  Ever 185 (68.8) 100 (69.0) 131 (61.5)
Age at diagnosis (y), n (%)
  ≤ 45 163 (60.6) 69 (47.6) 101 (47.4)
  > 45 106 (39.4) 76 (52.4) 112 (52.6)
  Mean ± SD 42.8 ± 6.4 44.3 ± 7.0 44.9 ± 5.1
Family history of breast cancerb, n (%)
  No 225 (84.6) 127 (88.8) 182 (85.9)
  Yes 41 (15.4) 16 (11.2) 30 (14.2)
Tumor subtype, n (%)
  HR+/HER2− 164 (61.0) 80 (55.2) 149 (70.0)
  HER2+ 59 (21.9) 33 (22.8) 40 (18.8)
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  TNBC 46 (17.1) 32 (22.1) 24 (11.3)
Tumor markers, n (%)
  ER+ 185 (68.8) 82 (56.6) 175 (82.2)
  PR+ 173 (64.3) 85 (58.6) 155 (72.8)
  HER2+ 59 (21.9) 33 (22.8) 40 (18.8)
a
Missing data for lifetime breastfeeding (Spain, n = 1)
b
Family history of breast cancer in a first-degree relative; missing data (USA, n = 3; Mexico, n = 2; Spain, n = 1)
Breast Cancer Res Treat. Author manuscript; available in PMC 2014 June 12.





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Breast Cancer Res Treat. Author manuscript; available in PMC 2014 June 12.







































































































































































































































































































































































































































































Breast Cancer Res Treat. Author manuscript; available in PMC 2014 June 12.
Cruz et al. Page 18
Table 3
Association between time since last full-term pregnancy and HER2+ status, by country
Country Subtype n OR (95% CI)
USA
HR+/HER2− 164 1.00
HER2+ 59 1.29 (0.71–2.34)
Mexico
HR+/HER2− 80 1.00
HER2+ 33 1.61 (0.67–3.82)
Spain
HR+/HER2− 149 1.00
HER2+ 40 2.50 (1.20–5.21)
Pooleda
HR+/HER2− 393 1.00
HER2+ 132 1.68 (1.12–2.52)
Pooledb
HR+/HER2− 393 1.00
HER2+ 132 1.78 (1.08–2.93)
a
Study site included as a random effect in logistic regression model
b
Adjusted for age at diagnosis (≤ 45 or > 45 y); study site included as a random effect in logistic regression model
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